Pilot Study: Miltefosine Gel (G-MTF) in Patients With Cutaneous Leishmaniasis
Launched by UNIVERSIDAD INDUSTRIAL DE SANTANDER ยท
Trial Information
Current as of November 12, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a new gel treatment called Miltefosine to see if it can help heal skin sores caused by a disease called cutaneous leishmaniasis (CL). This disease causes skin wounds, and the study is looking at whether applying Miltefosine gel directly on these sores every day for 28 days is safe and helps the wounds get better. Researchers will try different strengths of the gel to find out which works best and whether it causes any skin problems.
Adults of any gender who have uncomplicated cutaneous leishmaniasis may be able to join the study. Before starting, participants will visit the clinic for tests and to learn about the study. They will apply the gel daily on their sores, take weekly photos, and keep track of any symptoms. Follow-up visits will happen after 28 days and again three months later to check progress. This is an early-stage study to see if this treatment should be tested further in larger trials.
Gender
ALL
Eligibility criteria
About Universidad Industrial De Santander
The Universidad Industrial de Santander (UIS) is a prominent academic institution in Colombia, renowned for its commitment to advancing research and education in engineering, sciences, and healthcare. As a clinical trial sponsor, UIS leverages its extensive expertise and innovative approaches to conduct rigorous clinical studies that aim to enhance medical knowledge and improve patient outcomes. The university fosters collaboration among multidisciplinary teams, ensuring adherence to ethical standards and regulatory guidelines while contributing to the development of groundbreaking treatments and interventions. Through its research initiatives, UIS plays a pivotal role in addressing critical health challenges both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported